|Antibody & Protein Therapeutics Summit|
Antibodies in Oncology & Beyond
Antibody Drug Conjugates
Novel Protein Therapeutics
Although antibody-drug conjugates and protein therapeutics now play a significant role in the treatment and diagnosis of diseases, this field is continuously evolving with novel and innovative next-generation therapeutics on the horizon. Therefore, we invite you to attend the Antibody & Protein Therapeutics Summit to be held at the Royal Sonesta Harbor Court on July 11-12, 2017 in Baltimore, MD. The summit is the ideal venue to network with academic and pharmaceutical industry scientists, providing access to over 40 presentations from leading experts and will feature the latest advances in antibody and protein therapeutic research, including clinical findings.
This summit is comprised of three complimentary tracks that seek to drive the discovery, development and application of antibody & protein therapies. Track 1 – Antibodies in Oncology & Beyond will provide sessions exploring antibody discovery strategies and the development of antibodies and proteins for cancer immunotherapy and infectious diseases. Track 2 – Antibody Drug Conjugates will provide numerous sessions spanning basic discovery and development to important clinical findings. Track 3 – Novel Protein Therapeutics will provide innovative ideas in protein design and engineering. The sessions will also highlight advances in emerging antigen discovery in disease and applications with radioactive payloads.
Join us to network with colleagues to discuss the methods and tools used in developing effective next-generation antibody-drug conjugates and protein therapeutics to “drive the future of science.”
We hope to see you there!
The 2017 Advisory Committee
|2017 Program Director|
|Victor-Jeffrey Leyton, Université de Sherbrooke|
|2017 Advisory Board Members|
|Neeraj Agrawal, Amgen|
|Ahuva Nissim, Queen Mary University|
|Amandeep Gakhal, Sutro Biopharma|
|Ann White, University of Southampton|
|Bill Harriman , Crystal Bioscience|
|Birgit Schoeberl, Merrimack Pharmaceuticals|
|Elad Firnberg, Revolve Biotechnologies|
|Ernesto Freire, Johns Hopkins University|
|Nicolas Fischer, Novimmune SA|
|Gregory Adams, Eleven Biotherapeutics|
|Janos Luka, Walter Reed Army Institute of Research|
|Matthew Robinson, Immunome, Inc|
|Michael R. Dyson, IONTAS Ltd|
|Andreas Pahl, Heidelberg Pharma|
|Pedro Berraondo López, CIMA, University of Navarra|
|Darren Schofield, MedImmune|
|Seema Kumar, EMD Serono|
|Jamshid Tanha, University of Ottawa|
|Thomas Pillow, Genentech|
|Medha J. Tomlinson, Abbvie|
|Yan Chen, Genentech|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Morphotek® is a biotechnology company developing antibody-based therapies. In oncology, we focus on underlying disease pathways and overcoming immunosuppressive effects by tumors on immune-mediated therapies. As part of this approach, our ADC Services employ our REsidue-SPEcific Conjugation Technology™ (RESPECT™) and proprietary payloads to develop ADCs for Morphotek and our clients.
NanoTemper Technologies develops, produces and markets innovative technologies and instrumentation used by thousands of scientists worldwide. The company stands for a strong commitment to quality and high-precision instrumentation made in Germany. The experienced team of experts focuses on users' benefits by ensuring maximum efficiency for research in pharmaceutical and biotechnology industries.
BSI is well known for its PEAKS software suite and service platform for proteomics discovery and therapeutic protein characterization by LC-MS. The benchmark de novo sequencing capabilities offers advanced solutions for proteomic and therapeutic protein discovery as provided through peptide/protein identification & quantification, peptide mapping, PTMs and sequence variants.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.